Stem-cell transplantation for the treatment of advanced solid tumors

Springer Seminars in Immunopathology

Volumn 26, Issue 1-2, 2004, Pages 31-56

  Nieto, Yago ^a   Jones, Roy B ^b   Shpall, Elizabeth J ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic transplantation; Autologous stem cell transplantation; High dose chemotherapy; Solid tumor; Standard dose chemotherapy

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; PACLITAXEL; THIOTEPA; TRASTUZUMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG MEGADOSE; GERM CELL TUMOR; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BONE MARROW PURGING; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; FEMALE; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASMS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 11144333723     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00281-004-0160-8     Document Type: Review

References (152)

1. Anderson IC, Shpall EJ, Leslie DS, et al (1989) Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 15:4659
2. Antman K, Ayash L, Elias A, et al (1992) A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102
3. Antman KH, Rowlings PA, Vaughan WP, et al (1997) High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870
4. Ariel IM, Pack GT (1962) Treatment of disseminated melanoma with phenylalanine mustard (melphalan) and autogenous bone marrow transplants. Surgery 51:582
5. Ayash LJ, Elias A, Wheeler C, et al (1994) Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12:37
6. Ayash LJ, Elias A, Schwartz G, et al (1996) Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 14:2984
7. Ayash L, Elias A, Ibrahim J, et al (1998) High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer. J Clin Oncol 16:1000
8. Basser R, O'Neill A, Martinelli G, et al (2003) Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): first results from IBCSG trial 15-95. Proc Am Soc Clin Oncol 22:6a (abstr 20)
9. Bay JO, Fleury J, Choufi B, et al (2002) Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 30:95
10. Bearman SI, Overmoyer BA, Bolwell BJ, et al (1997) High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant 20:931
11. Ben-Yosef R, Or R, Nagler A, Slavin S (1996) Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 348:1242
12. Bergh J, Wiklund T, Erikstein B, et al (2000) Tailored fluoruracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 356:1384
13. Bertucci F, Viens P, Delpero JR, et al (2000) High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transplant 26:61
14. Bertuzzi A, Castagna L, Nozza A, et al (2002) High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 20:2181
15. Bertuzzi A, Castagna L, Quagliuolo V, et al (2003) Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour. Br J Cancer 89:1159
16. Bewick M, Chadderton T, Conlon M, et al (1999) Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant 24:377
17. Bewick M, Conlon M, Parissenti AM, et al (2001) Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res 10:759
18. Beyer J, Kramar A, Mandanas R, et al (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14:2638
19. Bhatia S, Abonour R, Porcu P, et al (2000) High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular experience. J Clin Oncol 18:3346
20. Biron P, Durand M, Roché H, et al (2002) High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French protocol. Proc Am Soc Clin Oncol 21:42a (abstr 167)
21. Bishop MR, Marchigiani D, Grasmeder S, et al (2003) Demonstration of clinical responses to adoptive cellular therapy using allogeneic T cells in metastatic breast cancer. Proc Am Soc Clin Oncol 22:164a (abstr 657)
22. Biaise D, Bay JO, Faucher C, et al (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103:435
23. Blay JY, Bouhour D, Ray-Coquard I, et al (2000) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 18:3643
24. Bokemeyer C, Kollmannsberger C, Meisner C, et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17:3450
25. Bregni M, Dodero A, Peccatori J, et al (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99:4234
26. Brenner MK, Rill DR, Moen RC, et al (1993) Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85
27. Broun ER, Nichols CR, Kneebone P, et al (1992) Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124
28. Broun ER, Nichols CR, Turns M, et al (1994) Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 73:1716
29. Broun ER, Sridhara R, Sledge GW, et al (1995) Tandem autotransplantion for the treatment of metastatic breast cancer. J Clin Oncol 13:2050
30. Broun ER, Nichols CR, Gize G, et al (1997) Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79:1605
31. Brugger W, Fetscher S, Hasse J, et al (1998) Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol 25 (Suppl 2):42
32. Burdach S, Kaick B van, Laws HJ, et al (2000) Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Ann Oncol 11:1451
33. Burdach S, Jurgens H (2002) High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 41:169
34. Burdach S, Meyer-Bahlburg A, et al (2003) High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 21:3072
35. Cagnoni PJ, Nieto Y, Shpall EJ, et al (1998) High-dose chemotherapy with autologous progenitor cell support as part of combined modality therapy for inflammatory breast cancer. J Clin Oncol 16:1661
36. Chevreau C, Droz JP, Pico JL, et al (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur Urol 23:213
37. Childs R, Chernoff A, Contentin N, et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750
38. Cornbleet MA, McElwain TJ, Kumar PJ, et al (1990) Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer 61:330
39. Crown JP, Lind M, Gould A, et al (2002) High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer and 4 or more involved axillary lymph nodes (4+ LN): The Anglo-Celtic I study. Proc Am Soc Clin Oncol 21:42a (abstr 166)
40. Crown, J, Perey L, Lind M, et al (2003) Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): The International Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol 22:23a (abstr 88)
41. Crump M, Gluck S, Stewart D, et al (2001) A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (AHPCT) compared to standard chemotherapy in women with metastatic breast cancer: A National Cancer Institute of Canada (NCIC) Clinical Trials Group study. Proc Am Soc Clin Oncol 20:21a (abstr 82)
42. Curé H, Battista C, Guastalla J, et al (2001) Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients with responsive low-burden advanced ovarian cancer: Preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 20:204a (abstr 815)
43. Damon LE, Wolf JL, Rugo HS, et al (2002) Long follow-up of patients with primary breast cancer and ≥10 involved axillary lymph nodes after high-dose chemotherapy and autologous stem cell transplant. Biol Blood Marrow Transplant 8:71a (abstr 37)
44. Deisseroth AB, Zu Z, Claxton D, et al (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow transplant in CML. Blood 83:3068
45. Dunphy ER, Spitzer G, Buzdar AU, et al (1990) Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207
46. Durando X, Lemaire JJ, Tortochaux J, et al (2003) High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 31:559
47. Eder JP, Antman K, Peters WP, et al (1986) High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4:646
48. Eibl B, Schwaighofer H, Nachbaur D, et al (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501
49. Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci USA 99:4592
50. Elias AD, Ayash LJ, Wheeler C, et al (1995) Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 15:373
51. Elias AD, Ibrahim J, Skarin AT, et al (1999) Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 17:1175
52. Elias AD, Ibrahim J, Richardson P, et al (2002) The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant 8:198
53. Elias AD, Skarin AT, Richardson P, et al (2002) Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant 8:326
54. Farha P, Spitzer G, Valdivieso M, et al (1983) High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small-cell lung carcinoma. Cancer 52:1351
55. Farquhar C, Basser R, Hetrick S, et al (2003) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev (1): CD003142 (http://www.cochrane.org/cochrane/revabstr/ AB003142.htm)
56. Farquhar C, Basser R, Marjoribanks J, Lethaby A (2003) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev (1): CD003139, (http://www.cochrane.org/ cochrane/revabstr/AB003139.htm)
57. Fetscher S, Brugger W, Engelhardt R, et al (1999) Standardand high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Ann Oncol 10:561
58. Gianni AM, Siena S, Bregni M, et al (1997) Efficacy, toxicity and applicability of high-dose chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 15:2312
59. Gianni A, Bonadonna G (2001) Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+). Proc Am Soc Clin Oncol 20:21a (abstr 80)
60. Goodwin W, Crowley J (1989) A retrospective comparison of high-dose BCNU with autologous marrow rescue plus radiotherapy vs IV BCNU plus radiation therapy in high grade gliomas. Proc Am Soc Clin Oncol 8:90
61. Harlin H, Artz AS, Mahowald M, et al (2004) Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8(+) IFN-gamma-producing T cells. Bone Marrow Transplant 33:491
62. Herzig R, Phillips G, Wolff S, et al (1984) Treatment of metastatic melanoma with intensive melphalan-BCNU combination chemotherapy and cryopreserved autologous bone marrow transplantation. Proc Am Soc Clin Oncol 3:264
63. Hu WW, Negrin RS, Stockerl-Goldstein K, et al (2000) Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. Biol Blood Marrow Transplant 6:58
64. Humblet Y, Symann M, Bosly A, et al (1987) Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 5:1864
65. Johnson DB, Thompson JM, Corwin JA, et al (1987) Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. J Clin Oncol 5:783
66. Jones RB, Shpall EJ, Ross M, et al (1990) AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer: current results. Proc Am Soc Clin Oncol 7:121
67. Jung U, Foley JE, Erdmann AA, et al (2003) CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 102:3439
68. Kessinger A, Petersen K, Bishop M, Schmit-Pokorny K (1994) High dose therapy with autologous hematopoietic stem cell rescue for patients with metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 13:A1674
69. Kim YS, Konoplev SN, Montemurro F, et al (2001) HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7:4008
70. Kolb EA, Kushner BH, Gorlick R, et al (2003) Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 21:3423
71. Krause DS, Fackler MJ, Civin CI, May WS (1996) CD34: structure, biology and clinical utility. Blood 87:1
72. Laport GF, Grad G, Grinblatt DL, Bitran JD, Williams SF ( 1998) High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Bone Marrow Transplant 21:127
73. Ledermann JA, Herd R, Maraninchi D, et al (2001) High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 12:693
74. Legros M, Dauplat J, Fleury J, et al (1997) High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results, J Clin Oncol 15:1302
75. Leyvraz S, Perey L, Rosti G, et al (1999) Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 17:3531
76. Lister J, Rybka WB, Donnenberg AD, et al (1995) Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate post-transplant period. Clin Cancer Res 1:607
77. Lotz J-P, Curé H, Janvier M, et al (1999) Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic breast cancer: results of the national protocol PEGASE 04 (in French). Hematol Cell Ther 41:71
78. Madan B, Broadwater G, Rubin P, et al (2000) Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate (AFM): a phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 19:48a
79. Margolin K, Doroshow JH, Ahn C, et al (1996) Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 14:2631
80. Meisenberg BR, Ross M, Vredenburgh JJ, et al (1994) Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk multi-node-positive malignant melanoma. J Natl Cancer Inst 85:1080
81. Mena O, Igarashi T, Srinivasan R, et al (2001) Immunologic mechanisms involved in the graft-vs-tumor (GVT) effect in renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation (NST). Blood 98:856a (abstr 3555)
82. + cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Clin Cancer Res 5:1035
83. Motzer RJ, Gulati SC, Crown JP, et al (1992) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550
84. Motzer RJ, Mazumdar M, Gulati SC, et al (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828
85. Motzer RJ, Mazumdar M, Bosl GJ, et al (1996) High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098
86. Motzer RJ, Mazumdar M, Bajorin DF, et al (1997) High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546
87. + hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 6:262
88. Negrier S, Escudier B, Lasset C, et al (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunotherapie. N Engl J Med 338:1272
89. Nichols CR, Tricot G, Williams SD, et al (1989) Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932
90. Nichols CR, Andersen J, Lazarus HM, et al (1992) High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 10:558
91. Nieto Y, Cagnoni PJ, Shpall EJ, et al (1999) Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV patients with minimal metastatic disease. Clin Cancer Res 5:1731
92. Nieto Y, Cagnoni PJ, Xu X, et al (1999) Predictive model for relapse after high-dose chemotherapy with peripheral blood progenitor cell support for high-risk primary breast cancer. Clin Cancer Res 5:3425
93. Nieto Y, Cagnoni PJ, Nawaz S, et al (2000) Evaluation of the predictive value of HER2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 18:2070
94. Nieto Y, Champlin RE, Wingard JR, et al (2000) Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant 6:476
95. Nieto Y, Cagnoni PJ, Shpall EJ, et al (2000) Phase I trial of docetaxel (DTX) combined with fixed doses of melphalan and carboplatin, with peripheral blood progenitor cell (PBPC) support in refractory malignancies. Proc Am Soc Clin Oncol 19:56a
96. Nieto Y, Nawaz S, Jones RB, et al (2002) Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20:707
97. Nieto Y, Nawaz S, Shpall EJ, et al (2004) Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 10:2609
98. Nieto Y, Franklin WA, Jones RB, et al (2004) Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant 10:415
99. Nieto Y, Rosinski S, Nawaz S, et al (2004) Prognostic evaluation of the early lymphocyte recovery in patients with advanced metastatic and non-metastastic breast cancer receiving high-dose chemotherapy with an autologous stem-cell transplant. Clin Cancer Res (in press)
100. Nieto Y, Vredenburgh JJ, Shpall EJ, et al (2004) Pilot study of concurrent administration of trastuzumab with high-dose cyclophosphamide, cisplatin, and BCNU, with autologous hematopoietic progenitor-cell support, in patients with advanced HER2-positive breast cancer. Clin Cancer Res (in press)
101. Nikcevich DA, Vredenburgh JJ, Broadwater G, et al (2002) Ten year follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Proc Am Soc Clin Oncol 21:415a
102. Nitz UA, Frick M, Mohrmann S, et al (2003) Tandem high dose chemotherapy versus dose-dense conventional chemotherapy for patients with high risk breast cancer: Interim results from a multicenter phase III trial. Proc Am Soc Clin Oncol 22:832a (abstr 3344)
103. Pecora AL, Lazarus HM, Jennis AA, et al (2003) Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant 8:536
104. Pedrazzoli P, Da Prada GA, Giorgiani G, et al (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94:2409
105. Peters WP, Eder JP, Henner WD, et al (1986) High-dose combination chemotherapy with autologous bone marrow support: a phase I trial. J Clin Oncol 4:646
106. Peters WP, Shpall EJ, Jones RB, et al (1988) High-dose combination chemotherapy with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368
107. Peters WP, Jones RB, Vredenburgh J, et al (1996) A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 15:121a
108. Peters WP, Ross M, Vredenburgh JJ, et al (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132
109. Peters WP, Rosner G, Vredenburgh J, et al (2001) Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/ NCIC Ma-13. Proc Am Soc Clin Oncol 20:21a
110. Phillips GL, Fay JW, Herzig GP, et al (1982) A phase I-II study; intensive BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea, NSC 409962) and autologous bone marrow transplantation for refractory cancer. Cancer 52:1792
111. Phillips GL, Wolff SN, Fay JW, et al (1986) Intensive BCNU chemotherapy and autologous bone marrow transplantation for malignant glioma. J Clin Oncol 4:639
112. Porrata LF, Ingle JN, Litzow MR, et al (2001) Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 28:865
113. Rick O, Bokemeyer C, Beyer J, et al (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19:81
114. Rini BI, Zimmerman T, Stadler WM, et al (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20:2017
115. Rizzieri DA, Vredenburgh JJ, Jones R, et al (1999) Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 17:3064
116. Rizzieri DA, Long GD, Vredenburgh JJ, et al (2001) Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells. Blood 98:420a (abstr 1764)
117. Roché, HH, Pouillart P, Meyer N, et al (2001) Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: the PEGASE 01 trial. Proc Am Soc Clin Oncol 20:27a (abstr 102)
118. Rodenhuis S, Westermann A, Holtkamp MJ, et al (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14:1473
119. Rodenhuis S, Bontenbal M, Beex LVAM, et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7
120. Rosenberg SA, Lotze MT, Muul LM, et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485
121. Ross AA, Cooper BW, Lazarus HM, et al (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605
122. Rosti G, Pico J-L, Wandt H, et al (2002) High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT): first results of a prospective randomized trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc Am Soc Clin Oncol 21:180a (abstr 716)
123. Salerno MG, Ferrandina G, Greggi S, et al (2001) High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplant 27:1017
124. Schmid P, Samonigg H, Nitsch T, et al (2002) Randomized trial of up front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:43a (abstr 171)
125. Schmoll HJ, Kollmannsberger C, Metzner B, et al (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083
126. Shapiro CL, Ayash L, Webb IJ, et al (1997) Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 15:674
127. Shea TC, Antman KH, Eder JP, et al (1988) Malignant melanoma: Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol 124:878
128. Shpall EJ, Jones RB, Bast RC, et al (1991) 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9:85
129. Shpall EJ, Bast RC, Joines WT, et al (1991) Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7:145
130. Shpall EJ, Jones RB, Bearman SI, et al (1994) Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28
131. Siegert W, Beyer J, Strohscheer I, et al (1994) High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 12:1223
132. Solano C, Badia B, Lluch A, et al (2001) Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 27:287
133. Somlo G, Doroshow JH, Forman SJ, et al (1997) High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 15:2882
134. Somlo G, Simpson JF, Frankel P, et al (2002) Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer 87:281
135. Souhami RL, Harper PG, Linch D, et al (1983) High-dose cyclophosphamide with autologous bone marrow transplantation for small-cell lung carcinoma of the bronchus. Cancer Chemother Pharmacol 10:205
136. Souhami RL, Finn G, Gregory WM, et al (1985) High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol 3:958
137. Souhami RL, Hajichristou HT, Miles DW, et al (1989) Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 24:321
138. Spitzer G, Farha P, Valdivieso M, et al (1986) High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 4:4
139. Stadtmauer EA, O'Neill A, Goldstein LJ, et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342:1069
140. Stiff PJ, Bayer R, Kerger C, et al (1997) High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 15:1309
141. Stiff PJ, Veum-Stone J, Lazarus HM, et al (2000) High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 133:504
142. Takvorian T, Parker LM, Hochberg FH, Canellos GP (1983) Autologous bone marrow transplantation: host effects of high-dose BCNU. J Clin Oncol 1:610
143. Tallman M, Gray R, Robert N, et al (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349:17
144. Thatcher D, Lind M, Morgenstern G, et al (1989) High-dose double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 63:1296
145. Ueno NT, Rondón G, Mirza NQ, et al (1998) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986
146. Ueno NT, Rizzo JD, Hegenbart U, et al (2003) International Bone Marrow Transplant Registry/The European Group for Blood and Marrow Transplantation (IBMTR/EBMT) review of allogeneic hematopoietic stem-cell transplantation (ALLO HSCT) in metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 22:832a (abstr 3345) (http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-003366- 00_21 -0015,00.asp)
147. Ueno NT, Cheng YC, Rondon G, et al (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102:3829
148. Vahdat L, Balmaceda C, Papadopoulos K, et al (2002) Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant 30:149
149. Viens P, Gravis G, Biaise D, et al (1995) High dose chemotherapy with bone marrow rescue for patients with FIGO stage III or IV common epithelial ovarian carcinoma responding to first line treatment. Proc Annu Meet Am Soc Clin Oncol 14:A811
150. Wolff SN, Herzig RH, Fay JW, et al (1989) High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 7:245
151. + peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplant 25:1165
152. Zander AR, Krüger W, Kröger N, et al (2002) High-dose chemotherapy with autologous hematopoietic stem-cell support (HSCS) vs standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. Proc Am Soc Clin Oncol 21:415a (abstr 1658)